Phase 2 RCT: Safety and immunogenicity of the AstraZeneca vaccine in children aged 6–17 years.
15 Jun, 2022 | 11:15h | UTCInvited Commentary: Increasing children’s global access to COVID-19 vaccines – The Lancet
Invited Commentary: Increasing children’s global access to COVID-19 vaccines – The Lancet